Management of chemotherapy-induced nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most disturbing side effects of cancer treatment. Research in anti-emetic therapy progressed gradually since the early eighties and the development of anti-emetic agents continues. This review focuses on the current management of CINV based on the most recent guidelines and adherence to the latter is examined more carefully. Setrons (5HT3 receptor antagonists), corticosteroids and NK-1 receptor antagonists are the cornerstones of anti-emetic therapy. The latest developed palonosetron and casopitant proved to be highly promising in clinical trials. Other types include benzodiazepines, cannabinoids and olanzapine. Various risk factors contribute to the overall risk of developing CINV, such as patient characteristics, emetogenic potency of the chemotherapeutic agents and correct prevention of CINV. Current guidelines determine which is the right preventive regimen for each cancer patient at risk for experiencing CINV. Adherence to this guidelines and implementation in daily practice seem to be below the optimal level. In Belgium, authorities use the guidelines as a base for reimbursement and this has increased the level of implementation.
Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium. Florence.vanryckeghem@ugent.be
F
F
Van Ryckeghem
S
S
Van Belle
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009325:Nausea / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014839:Vomiting / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy
D000932:Antiemetics; D000970:Antineoplastic Agents